Navigation Links
Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
Date:10/23/2013

SEATTLE Fred Hutchinson Cancer Research Center tomorrow will celebrate the grand opening of a state-of-the-art HIV vaccine laboratory in Cape Town,

South Africa. The lab will be one of Africa's most advanced scientific facilities.

The lab is part of the HIV Vaccine Trials Network, which is headquartered at Fred Hutch in Seattle and is the world's largest network dedicated to testing vaccine candidates for the prevention of HIV. The opening of the Cape Town HVTN Immunology Laboratory illustrates how the Hutch is constantly seeding new, international collaborations that bring researchers together to find a vaccine to end HIV.

The lab will analyze results from upcoming trials of innovative new HIV vaccines and will help African scientists advance their own research. The trials will test new and improved versions of vaccines which, in a trial conducted in Thailand, were shown to reduce the rate of HIV infection by about 30 percent the most promising HIV-vaccine results to date.

"We wanted to test the vaccines in a place where they could have the biggest benefit, and we needed the infrastructure to do that without shipping samples all the way back to Seattle," said HVTN Laboratory Center Director Julie McElrath, M.D., Ph.D., senior vice president and director of the Vaccine and Infectious Disease Division at Fred Hutch.

HVTN staff members have spent the past two years fanning out across southern Africa, scouting trial sites and laying the foundation for trials that will involve about two dozen new sites and several thousand patients. Phase 1 studies are already taking place to make sure the vaccines are safe. The goal is to launch a large phase 3 trial to confirm effectiveness and determine any side effects in 2015.

The lab will analyze blood samples from trial participants to see how their immune systems react to the vaccine and interact with the virus. If the trial confirms the Thai trial's results, researchers may learn which responses future vaccines should aim to produce. That would position scientists to launch smaller, more targeted trials that try to quickly zero in on an effective vaccine.

"If we get the right results, we could potentially make the vaccine far more effective in a relatively short period of time," said Larry Corey, M.D., Fred Hutch's president and director and HVTN principal investigator. Corey launched HVTN in 1999.

The Cape Town HVTN Immunology Laboratory received critical funding from the Bill & Melinda Gates Foundation and represents a partnership between Fred Hutch and South Africa's research community.

The lab will collaborate with local researchers and aim to increase the country's scientific capacity in the fight against HIV, said Erica Andersen-Nissen, director of the lab.

"That's a really important goal to partner with African scientists and clinicians to lay a foundation for research that extends beyond the HVTN," she said.


'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert  

Related medicine news :

1. Hutchinson Center president elected to American Academy of Art and Sciences
2. Mount Sinai finds value and limitations of patient assistance programs for women with breast cancer
3. Like a Celebrity Concierge Brings Fun to the Fight with #ShopForACure Breast Cancer Charity Shopping Soiree at Copia NYC
4. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
5. Airelle Skin Participates in Long Island Breast Cancer Awareness Event
6. Internet users more likely to engage in cancer-preventive behaviors
7. Study Examines Connections Between Depression and Breast Cancer, Allsup Reports
8. Rapid method to detect BRAF mutations in cancer tissue samples
9. Investigational PARP inhibitor promising in BRCA-related cancers
10. New program makes prostate cancer treatment decisions easier
11. Coffee consumption reduces risk of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology: